News for AQSZF Stock

Aequus Reports Second Quarter 2023 Financial Highlights and General Update Aequus Announces Zimed PF Now Available in Canada Aequus Announces Zimed PF Website Launch Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) Aequus Provides General Update and First Quarter 2023 Financial Highlights Aequus Provides General Update and Fiscal 2022 Financial Results Aequus Grants Stock Options Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%) Aequus Reports Third Quarter 2022 Financial Highlights Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free) Aequus Reports Second Quarter 2022 Financial Highlights and General Update Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc. Aequus Resumes Trading on TSX Venture Exchange Aequus Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products Aequus Provides General Update and Reports Record 2021 Financial Results Aequus Provides Update on Delay in Filing Annual Financial Statements Aequus Provides Update on Delay in Filing Annual Financial Statements Aequus Provides Update on Delay in Filing Annual Financial Statements Aequus Announces Delay in Filing Annual Financial Statements Aequus Announces Short Term Loan Aequus Announces Director Resignation Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication Aequus Reports Third Quarter 2021 Financial Highlights Aequus Reports Second Quarter 2021 Financial Highlights Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise Aequus and reVision to Collaborate on Stargardt Disease Program Aequus and reVision to Collaborate on Stargardt Disease Program Aequus Provides Commercial Update Aequus Provides General Update and First Quarter 2021 Financial Highlights Aequus Provides General Update and Reports Record 2020 Financial Results Aequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference Aequus Launches Evolve Eyedrops to Eye Care Professionals in Canada Aequus Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada